secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001104659-24-078207
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics gets UK MHRA approval for LYTENAVA (bevacizumab gamma) for wet AMD
--------------------------------------------------------------------------------

- UK MHRA granted Marketing Authorization for LYTENAVA (bevacizumab gamma) to treat wet age-related macular degeneration.
- LYTENAVA is the first and only authorized ophthalmic bevacizumab formulation for wet AMD in the EU and UK.
- Approval leveraged EMA positive opinion under the new International Recognition Procedure.
- This regulatory milestone supports Outlook's commercial strategy in the UK market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/0001104659-24-078207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924078207/tm2418995d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer